Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REKHA JOHN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1619979846
CMS profile
118220
Location
KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$77.93

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $77.93 6

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REKHA JOHN

NPI 1619979846 · CMS profile ID 118220

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
REKHA JOHN, NPI 1619979846, CMS profile ID 118220, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $77.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Relypsa, Inc. $12.2109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683899319 CMS
AstraZeneca Pharmaceuticals LP $13.7404/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685168593 CMS
Otsuka America Pharmaceutical, Inc. $18.1404/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687410079 CMS
Relypsa, Inc. $11.2002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683898025 CMS
Otsuka America Pharmaceutical, Inc. $14.0301/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687410077 CMS
AKEBIA THERAPEUTICS INC $8.6101/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706564589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $77.93 6
PY2020 $119.67 2
PY2022 $404.00 18
PY2023 $539.51 20
PY2024 $2,789.07 18
PY2025 $388.84 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $499,069.81 26
PY2024 Principal investigator $549,482.70 50
PY2023 Principal investigator $376,752.37 57
PY2022 Recipient $7,645.61 7
PY2022 Principal investigator $353,881.30 372
PY2021 Principal investigator $168,644.86 191
PY2020 Principal investigator $154,822.49 45
PY2019 Principal investigator $231,281.89 292

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

379 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 12/19/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293779
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 12/19/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293781
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 12/19/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293783
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 11/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293785
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 11/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293787
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 11/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293789
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 11/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293791
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 11/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293793
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293579
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293581
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293583
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293585
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293587
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293589
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293591
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293593
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293595
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293597
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293599
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293795
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 10/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293797
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $15,131.00 10/10/2022 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 932268337
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293551
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293553
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293555
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293557
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293559
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293561
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293563
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293565
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293567
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293569
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293571
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293573
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293575
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 09/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293577
Recipient Ardelyx, Inc. $50.00 09/06/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149183
Principal investigator 1 Ardelyx, Inc. $50.00 09/06/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150673
Principal investigator 3 Ardelyx, Inc. $75.00 08/22/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149149
Recipient Ardelyx, Inc. $3,200.00 08/22/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149179
Recipient Ardelyx, Inc. $1,076.81 08/22/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149181
Principal investigator 5 Ardelyx, Inc. $3,200.00 08/22/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150657
Principal investigator 2 Ardelyx, Inc. $1,076.81 08/22/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150659
Principal investigator 5 Ardelyx, Inc. $75.00 08/22/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150661
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293531
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293533
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293535
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293537
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293539
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293541
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293543
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293545
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293547
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293549
Principal investigator 1 Ardelyx, Inc. $15,496.85 08/10/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149145
Principal investigator 3 Ardelyx, Inc. $3,200.00 08/10/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149147
Principal investigator 2 Ardelyx, Inc. $3,200.00 08/10/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149211
Principal investigator 5 Ardelyx, Inc. $15,496.85 08/10/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150637
Principal investigator 3 Ardelyx, Inc. $3,200.00 08/10/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150639
Principal investigator 4 Ardelyx, Inc. $3,200.00 08/10/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150641
Principal investigator 2 Ardelyx, Inc. $3,200.00 08/03/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149189
Principal investigator 1 Ardelyx, Inc. $3,200.00 08/03/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150627
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,875.00 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293505
Principal investigator 1 AKEBIA THERAPEUTICS INC $624.38 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293507
Principal investigator 1 AKEBIA THERAPEUTICS INC $200.00 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293509
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293511
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293513
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293515
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293517
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293519
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293521
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293523
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,680.50 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293525
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,680.50 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293527
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 07/25/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293529
Principal investigator 1 Ardelyx, Inc. $30.00 07/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149143
Principal investigator 2 Ardelyx, Inc. $30.00 07/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150565
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,300.00 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293483
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,792.14 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293485
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,125.00 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293487
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293489
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293491
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293493
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293495
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293497
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293499
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293501
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 06/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293503
Principal investigator 2 Ardelyx, Inc. $270.00 06/01/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149141
Principal investigator 3 Ardelyx, Inc. $270.00 06/01/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150413
Principal investigator 1 AKEBIA THERAPEUTICS INC $597.38 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293459
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293461
Principal investigator 1 AKEBIA THERAPEUTICS INC $783.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293463
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293465
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293467
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293469
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293471
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293473
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293475
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293477
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293479
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293481
Principal investigator 1 Ardelyx, Inc. $500.00 04/28/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149129
Principal investigator 3 Ardelyx, Inc. $500.00 04/28/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149701
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $31,371.32 04/21/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES KINSTON OFFICE
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 904835181
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293419
Principal investigator 1 AKEBIA THERAPEUTICS INC $597.38 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293421
Principal investigator 1 AKEBIA THERAPEUTICS INC $67.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293423
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293425
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293427
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293429
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293431
Principal investigator 1 AKEBIA THERAPEUTICS INC $634.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293433
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293435
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293437
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293439
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293441
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293443
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293445
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293447
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293449
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293451
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293453
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293455
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293457
Principal investigator 2 Ardelyx, Inc. $3,200.00 04/20/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149123
Principal investigator 3 Ardelyx, Inc. $3,200.00 04/20/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149197
Principal investigator 4 Ardelyx, Inc. $3,200.00 04/20/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149561
Principal investigator 4 Ardelyx, Inc. $3,200.00 04/20/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149563
Principal investigator 3 Ardelyx, Inc. $500.00 03/29/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149139
Recipient Ardelyx, Inc. $500.00 03/29/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149177
Principal investigator 5 Ardelyx, Inc. $500.00 03/29/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149209
Principal investigator 1 Ardelyx, Inc. $500.00 03/29/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149541
Principal investigator 2 Ardelyx, Inc. $500.00 03/29/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149543
Principal investigator 1 Ardelyx, Inc. $500.00 03/29/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149545
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290741
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290743
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290745
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290747
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290749
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290751
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290753
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290755
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290757
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290759
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290761
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290763
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290765
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290767
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290769
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290771
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290773
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290775
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290777
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290779
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290781
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290785
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290787
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290789
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290791
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290793
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290795
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290797
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290799
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290801
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290803
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290805
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290807
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290809
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290811
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290813
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290815
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290817
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290819
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290821
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290823
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290825
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290827
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290829
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290831
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290833
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290835
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290837
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290839
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290841
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290843
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290845
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290847
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290849
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290851
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290853
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290855
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290857
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290859
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290861
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290863
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290865
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290867
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290869
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290871
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290873
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290875
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290877
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290879
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290881
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290883
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290885
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290887
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290889
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290891
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290893
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290895
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290897
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290899
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290901
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290903
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290905
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290907
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290909
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885290911
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291205
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291207
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291209
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291247
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291249
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291251
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291253
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291255
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291257
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291259
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291261
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291263
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291265
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291267
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291269
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291271
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291273
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291275
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291277
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291279
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291281
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291283
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291285
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291287
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291289
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291291
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291293
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291295
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291297
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291299
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291301
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291303
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291305
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291307
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291309
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291311
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291313
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291315
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291317
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291319
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291321
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291323
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291325
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291327
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291329
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291331
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291333
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291335
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291337
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291339
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291341
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291343
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291345
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291347
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291349
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291351
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291353
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291355
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291357
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291359
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291361
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291363
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291365
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291367
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291369
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291371
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291373
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291375
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291377
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291379
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291381
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291383
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291385
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291387
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291389
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291391
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291393
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291395
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291397
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291399
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291401
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291403
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291405
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291407
Principal investigator 1 AKEBIA THERAPEUTICS INC $34.00 03/24/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES PLLC
AKB-6548-CI-0014 No dispute reported 06/30/2026 885291409
Principal investigator 1 AKEBIA THERAPEUTICS INC $800.00 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293385
Principal investigator 1 AKEBIA THERAPEUTICS INC $597.38 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293387
Principal investigator 1 AKEBIA THERAPEUTICS INC $25.00 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293389
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293391
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293393
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293395
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293397
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293399
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293401
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293403
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293405
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293407
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293409
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293411
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293413
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293415
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 03/22/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293417
Principal investigator 4 Ardelyx, Inc. $500.00 03/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149137
Principal investigator 2 Ardelyx, Inc. $500.00 03/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149187
Principal investigator 4 Ardelyx, Inc. $500.00 03/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149195
Principal investigator 1 Ardelyx, Inc. $500.00 03/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149207
Principal investigator 5 Ardelyx, Inc. $500.00 03/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149429
Principal investigator 2 Ardelyx, Inc. $500.00 03/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149431
Principal investigator 1 Ardelyx, Inc. $500.00 03/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149433
Principal investigator 5 Ardelyx, Inc. $500.00 03/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149435
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293341
Principal investigator 1 AKEBIA THERAPEUTICS INC $100.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293343
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,100.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293345
Principal investigator 1 AKEBIA THERAPEUTICS INC $400.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293347
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293349
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293351
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293353
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293355
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293357
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293359
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293361
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293363
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293365
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293367
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293369
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,201.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293371
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,201.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293373
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293375
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293377
Principal investigator 1 AKEBIA THERAPEUTICS INC $634.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293379
Principal investigator 1 AKEBIA THERAPEUTICS INC $634.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293381
Principal investigator 1 AKEBIA THERAPEUTICS INC $634.50 02/18/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293383
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $9,627.95 02/11/2022 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES KINSTON OFFICE
A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin No dispute reported 06/30/2026 904834501
Recipient Ardelyx, Inc. $2,418.80 02/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149171
Recipient Ardelyx, Inc. $250.00 02/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149173
Recipient Ardelyx, Inc. $150.00 02/07/2022 Covered Recipient Physician STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149175
Principal investigator 3 Ardelyx, Inc. $2,418.80 02/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149335
Principal investigator 3 Ardelyx, Inc. $250.00 02/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149337
Principal investigator 5 Ardelyx, Inc. $150.00 02/07/2022 Non-covered Recipient Entity
INTERSPOND LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149339
Principal investigator 1 AKEBIA THERAPEUTICS INC $317.25 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293303
Principal investigator 1 AKEBIA THERAPEUTICS INC $135.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293305
Principal investigator 1 AKEBIA THERAPEUTICS INC $135.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293307
Principal investigator 1 AKEBIA THERAPEUTICS INC $459.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293309
Principal investigator 1 AKEBIA THERAPEUTICS INC $25.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293311
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293313
Principal investigator 1 AKEBIA THERAPEUTICS INC $783.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293315
Principal investigator 1 AKEBIA THERAPEUTICS INC $783.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293317
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293319
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293321
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293323
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293325
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293327
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293329
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293331
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293333
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,599.75 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293335
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293337
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,599.75 01/21/2022 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885293339
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $40,168.81 01/07/2022 Non-covered Recipient Entity
FRENOVA MEDICAL CARE
PHASE 3B, RANDOMIZED, OPEN-LABEL, SPONSOR-BLIND, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT, ONCE DAILY (QD) AND THREE TIMES WEEKLY (TIW) FOR THE MAINTENANCE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) No dispute reported 06/30/2026 933760345